Sign in to view content

A Model to Predict the 3-Year Risk of Needing Treatment for Diabetic Macular Edema

Bobeck S Modjtahedi, MD

Video
Published 2018

Related

Diabetic Retinopathy 1 Symposium
Annual Meeting Talks
2020
Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial
Rishi P. Singh, MD
Annual Meeting Talks
2018
Insights Into the Progression of Diabetic Retinopathy Severity Among Primary Care Patients With Diabetes in the United States
Geeta A. Lalwani, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more